On cancer incidence in multiple sclerosis and effects of immunomodulatory treatments

Abstract

Feigin discusses the study of breast cancer risk and treatment of multiple sclerosis by Copaxone. The apparent hazard ratios for breast cancer calculated for Copaxone and beta interferon were not signicant, therefore it is difficult to draw any conclusions from this relatively limited population with fewer than 4 events, especially when the results are based on a particular analysis model, involving a set of assumptions, and which included the use of time-dependent covariates which were dened in a very specific way.